[A26-65] Nivolumab/relatlimab (melanoma) – Benefit assessment according to §35a Social Code Book V
Last updated 01.09.2026
Project no.:
A26-65
Commission:
Commission awarded on 29.05.2026 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Cancer
Adults and adolescents 12 years of age and older with advanced (unresectable or metastatic) melanoma with tumour cell programmed cell death ligand 1 expression < 1%; first-line treatment
- Adults: hint of a minor added benefit
- Adolescents 12 years of age and older: added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://doi.org/10.60584/A26-65